Alexion price target raised to $205 from $125 at Deutsche Bank Deutsche Bank raised its price target for shares of Alexion Pharmaceuticals to $205 citing upside potential from the company's launch of Asfotase Alfa for severe Hypophosphatasia. The firm keeps a Buy rating on the stock.
Alexion CEO Dr. Leonard Bell retired as of March 31 Dr. Leonard Bell, the principal founder and CEO of Alexion Pharmaceuticals retired from Alexion effective March 31, after serving as CEO for twenty-three years. No severance was paid to Dr. Bell in connection with his retirement. On April 1, Alexion entered into a Consulting Agreement and a Letter Agreement with Dr. Bell. Dr. Bell continues to serve as Alexion's Chairman of the Board of Directors.